Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM)- Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2096
https://www.valueinhealthjournal.com/article/S1098-3015(15)04172-8/fulltext
Title : Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM)- Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04172-8&doi=10.1016/j.jval.2015.09.2096
First page : A607
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 1513
Categories :
Tags :
Regions :
ViH Article Tags :